Holen Sie sich die Stockscreener-App
1.04
8.77%
-0.10
Handel nachbörslich:
1.04
Schlusskurs vom Vortag:
$1.14
Offen:
$1.2
24-Stunden-Volumen:
252.12K
Relative Volume:
0.95
Marktkapitalisierung:
$21.93M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-52.53M
KGV:
-0.2842
EPS:
-3.66
Netto-Cashflow:
$-39.93M
1W Leistung:
-20.00%
1M Leistung:
-39.18%
6M Leistung:
-29.25%
1J Leistung:
-36.59%
1-Tages-Spanne:
$1.011
$1.2199
1-Wochen-Bereich:
$1.011
$1.34
52-Wochen-Spanne:
$0.9397
$3.10
Unity Biotechnology Inc Stock (UBX) Company Profile
Firmenname
Unity Biotechnology Inc
Sektor
Branche
Telefon
(650) 416-1192
Adresse
285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
Vergleichen Sie UBX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UBX
Unity Biotechnology Inc
|
1.04 | 21.93M | 0 | -52.53M | -39.93M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Unity Biotechnology Inc Stock (UBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-11-16 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-01-04 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-11-10 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-06-28 | Hochstufung | Citigroup | Sell → Buy |
| 2021-06-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-16 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-08-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-18 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-08-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-08-17 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-07-28 | Eingeleitet | ROTH Capital | Buy |
| 2019-12-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-03-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Eingeleitet | Mizuho | Buy |
| 2018-05-29 | Eingeleitet | Citigroup | Buy |
| 2018-05-29 | Eingeleitet | Goldman | Neutral |
| 2018-05-29 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Unity Biotechnology Inc Aktie (UBX) Neueste Nachrichten
What is HC Wainwright’s Estimate for UBX FY2026 Earnings? - Defense World
Unity Biotechnology (NASDAQ:UBX) Price Target Lowered to $4.00 at Chardan Capital - Defense World
H.C. Wainwright cuts Unity Biotechnology target to $4; keeps buy rating - Investing.com Australia
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study - MSN
H.C. Wainwright cuts Unity Biotechnology target to $4; keeps buy rating By Investing.com - Investing.com South Africa
UNITY Biotechnology tanks on mixed results for eye disease drug - The Pharma Letter
Mizuho maintains Unity Biotechnology Outperform rating By Investing.com - Investing.com South Africa
Chardan Cuts Price Target on Unity Biotechnology to $4 From $6, Keeps Buy Rating - Marketscreener.com
Mizuho maintains Unity Biotechnology Outperform rating - Investing.com India
Unity Biotechnology (NASDAQ:UBX) Price Target Cut to $4.00 by Analysts at HC Wainwright - Defense World
UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE - EIN News
Sector Update: Health Care Stocks Rise Late Afternoon - TradingView
Sector Update: Health Care - TradingView
Unity Biotechnology Shares Decline After Diabetic Edema Treatment Misses Primary Endpoint - Marketscreener.com
UNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trial - MSN
HC Wainwright Adjusts Unity Biotechnology Price Target to $4 From $8, Maintains Buy Rating - Marketscreener.com
UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema - Yahoo Finance
Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls - Benzinga
Unity Biotechnology, Inc. Announces Topline Results from the ASPIRE Phase 2B Study in Diabetic Macular Edema - Marketscreener.com
UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema - GlobeNewswire
New DME Treatment Matches Standard Care: Phase 2b Shows Promising Vision Gains - Stock Titan
China’s Plans for a $900 Billion Space Project, but Can It Catch Up to SpaceX? - The Globe and Mail
UNITY Biotechnology to Host Virtual Investor Event Featuring Phase 2b ASPIRE Study Results for UBX1325 in Diabetic Macular Edema - Nasdaq
UNITY Biotechnology to Host Virtual Investor Event to - GlobeNewswire
Key Phase 2b Data Coming: UNITY's DME Treatment Could Transform Eye Disease Care - Stock Titan
Where Will QuantumScape Stock Be in 3 Years? - The Globe and Mail
This Micro Cap Continues This Week's Dominance Amid New CEO Appointment - The Globe and Mail
RECONAFRICA ANNOUNCES ACCELERATION OF DRILLING INTO Q2 2025 AND A CORPORATE UPDATE - The Globe and Mail
3 Reasons to Avoid AIR and 1 Stock to Buy Instead - The Globe and Mail
This Media Stock Is Finding Serious Success Prior To Opening Bell - The Globe and Mail
Unity Biotechnology Reports 2024 Financial Results and Updates - MSN
Unity Biotechnology announces upcoming trial data and new board of directors member - Ophthalmology Times
Chardan Capital Has Bullish Outlook for UBX FY2025 Earnings - Defense World
HC Wainwright Has Strong Estimate for UBX FY2025 Earnings - Defense World
Analysts Issue Forecasts for UBX Q1 Earnings - Defense World
Unity Biotechnology (NASDAQ:UBX) Receives “Buy” Rating from Chardan Capital - Defense World
UNITY Biotechnology appoints Yehia Hashad to its board -March 10, 2025 at 10:40 am EDT - Marketscreener.com
Unity Biotechnology Appoints Dr. Yehia Hashad to Board - TipRanks
UNITY Biotechnology Appoints Industry Leader and - GlobeNewswire
UNITY Biotech Strengthens Board with CMO Appointment Before Key Trial Results - StockTitan
Buy Rating Reaffirmed for Unity Biotechnology Amid Promising Developments in DME Treatment - TipRanks
Unity Biotechnology reports Q4 EPS (50c) vs. (28c) last year - TipRanks
UNITY Biotechnology Reports Q4 and Full Year 2024 Financial Results and Anticipates ASPIRE Study Data on UBX1325 for Diabetic Macular Edema - Nasdaq
Unity Biotechnology, Inc. SEC 10-K Report - TradingView
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates - GlobeNewswire
Canadian Investment Regulatory Organization Trading HaltRCK - The Globe and Mail
Korro Bio CFO takes medical leave, interim officers appointed - Investing.com
Annovis Bio (NYSE: ANVS) CEO to Present at Oppenheimer Healthcare Conference - The Globe and Mail
Unity Biotechnology CEO Anirvan Ghosh sells shares worth $1,431 - MSN
Could 2025 Be a Repeat of 2022 for Big Tech? - The Globe and Mail
Unity Biotechnology CFO sells shares worth $341 By Investing.com - Investing.com Nigeria
Finanzdaten der Unity Biotechnology Inc-Aktie (UBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.05%
1.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):